TRENDING :  Market Movers  |  Top 50   FDX (-2.8%)    SPY (-1.93%)    AMZN (-3%)    VXXB (11.47%)    WYNN (-3.5%)    XLE (-2.71%)    XLF (-2.77%)    XLU (0.73%)    XRX (-5.6%)    ZUO (-14.06%)    BA (-2.83%)    BAC (-4.16%)    BIIB (-4.49%)    BPTH (18.94%)    CFMS (-1.65%)    CHKP (-0.58%)    CLRB (-6.1%)    CSIQ (-2.75%)    CVRS (2.72%)    CZZ (-7.45%)    DIS (-0.4%)    EVRI (-1.11%)    SQ (-4.39%)    TAC (-1.18%)    TARO (-0.12%)

 AGEN - Agenus Inc.

$2.82 [-0.17][-5.37%]

Next Earnings

5/6/2019

BMO

Recommend
Trade Idea »



OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $AGEN

TRENDING ARTICLES



3 Top Growth Stocks to Buy Right Now

03/20/19
Growth stocks are known for their market beating returns which also explains why such stocks often command a premium in the stock market For a company to outperform its industry and the market it should have a sustainable economic moat and operate in a high potential industry

Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up

03/14/19
Agenus Inc AGEN announced that it has received 7 5 million in cash as milestone payment from Gilead Sciences GILD after the FDA accepted the company s investigational new drug IND application for AGEN1423 AGEN1423 is a first in class molecule currently developed in partnership with

Agenus Inc (AGEN) Q4 2018 Earnings Conference Call Transcript

03/14/19
Image source The Motley Fool Agenus Inc NASDAQ AGEN Q4 160 2018 Earnings Conference Call March 14 2019 8 30 a m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared Remarks Operator

Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates

03/14/19
Agenus AGEN came out with a quarterly loss of 0 40 per share versus the Zacks Consensus Estimate of a loss of 0 28 This compares to loss of 0 35 per share a year ago These figures are adjusted for non recurring items This quarterly report represents an earnings surprise of 42 86

Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

03/08/19
Gilead Sciences Inc GILD presented a series of data at the 2019 Conference on Retroviruses and Opportunistic Infections CROI in Seattle The company announced results from two studies evaluating the resistance profile of a once daily single tablet HIV regimen Biktarvy bictegravir

Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

03/07/19
Gilead Sciences Inc GILD presented a series of data at the 2019 Conference on Retroviruses and Opportunistic Infections CROI in Seattle The company announced results from two studies evaluating the resistance profile of a once daily single tablet HIV regimen Biktarvy bictegravir

The 3 Oldest Members of Biotech's Billion-Burned Club

03/04/19
Believe it or not 160 most professionals in the weird world of drug development would rather be lucky than smart That s because 99 99 of potential new drugs that look great in a petri dish eventually lose their luster before earning a nickel Every time an attempt to develop a